Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma

Background Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols. Aims This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation. Mat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical apheresis 2021-08, Vol.36 (4), p.628-633
Hauptverfasser: Yang, John Jeongseok, Ryu, Kyong‐Suk, Kim, Jin Seok, Chung, Yousun, Kim, Hyungsuk, Hwang, Sang‐Hyun, Oh, Heung‐Bum, Ko, Dae‐Hyun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 633
container_issue 4
container_start_page 628
container_title Journal of clinical apheresis
container_volume 36
creator Yang, John Jeongseok
Ryu, Kyong‐Suk
Kim, Jin Seok
Chung, Yousun
Kim, Hyungsuk
Hwang, Sang‐Hyun
Oh, Heung‐Bum
Ko, Dae‐Hyun
description Background Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols. Aims This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation. Materials & Methods Alternative use of group A or B plasma (incompatible plasma) was inevitable during the shortage of group AB plasma. Experience from select number of patients during the period of extreme group AB plasma shortage is described. Results The result of alternative use of group A or B plasma was within expectation, showing effective reduction of isoagglutinin titers for pre‐operative desensitization and efficacy for treatment of post‐operative patients. No immediate hemolytic transfusion reaction was reported. Discussion While validation in a larger cohort of patients is necessary, our limited experience have shown satisfactory clinical outcomes without adverse events. Conclusions Use of incompatible group A or B plasma is a viable option when group AB plasma is limited.
doi_str_mv 10.1002/jca.21904
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2522400275</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2522400275</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3534-fb5862687af4ac158991063d18aa0d3e272ded5e5681314557428d8aa38630223</originalsourceid><addsrcrecordid>eNp1kT1PwzAQhi0EoqUw8AdQJBYY0vrrkngsVflSJRaYIzdx2lRJHOwY6L_HJS0DEpPtu8ePTvcidEnwmGBMJ5tMjikRmB-hIcEiCQnB5BgNccxYSDmIATqzdoMxFoLBKRowJgAD8CFq5h-ycrIrdRPoIrCyUN12d3O2bFZB2WS6bn17WamgraStZVBoE3RrZWSrXFdmh7L6ytayWakgd2b31a616aR_e9n0bk-do5NCVlZd7M8Rerufv84ew8XLw9NsuggzBoyHxRKSiEZJLAsuMwKJEARHLCeJlDhnisY0VzkoiBLCCAeIOU1y32RJxDClbIRuem9r9LtTtkvr0maqqmSjtLMpBUq5X10MHr3-g260M42fzlMgeEwAIk_d9lRmtLVGFWlrylqabUpwugsh9SGkPyF49mpvdMta5b_kYesemPTAZ1mp7f-m9Hk27ZXf2SuPZg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2559471556</pqid></control><display><type>article</type><title>Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Yang, John Jeongseok ; Ryu, Kyong‐Suk ; Kim, Jin Seok ; Chung, Yousun ; Kim, Hyungsuk ; Hwang, Sang‐Hyun ; Oh, Heung‐Bum ; Ko, Dae‐Hyun</creator><creatorcontrib>Yang, John Jeongseok ; Ryu, Kyong‐Suk ; Kim, Jin Seok ; Chung, Yousun ; Kim, Hyungsuk ; Hwang, Sang‐Hyun ; Oh, Heung‐Bum ; Ko, Dae‐Hyun</creatorcontrib><description>Background Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols. Aims This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation. Materials &amp; Methods Alternative use of group A or B plasma (incompatible plasma) was inevitable during the shortage of group AB plasma. Experience from select number of patients during the period of extreme group AB plasma shortage is described. Results The result of alternative use of group A or B plasma was within expectation, showing effective reduction of isoagglutinin titers for pre‐operative desensitization and efficacy for treatment of post‐operative patients. No immediate hemolytic transfusion reaction was reported. Discussion While validation in a larger cohort of patients is necessary, our limited experience have shown satisfactory clinical outcomes without adverse events. Conclusions Use of incompatible group A or B plasma is a viable option when group AB plasma is limited.</description><identifier>ISSN: 0733-2459</identifier><identifier>EISSN: 1098-1101</identifier><identifier>DOI: 10.1002/jca.21904</identifier><identifier>PMID: 33950554</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>ABO Blood-Group System ; Agglutinins - chemistry ; Apheresis ; Blood Banks - supply &amp; distribution ; Blood Group Incompatibility - therapy ; desensitization ; Graft Survival ; Hemolysis ; Humans ; incompatible ; Kidney Transplantation - adverse effects ; Patient Safety ; Plasma ; Plasma - immunology ; Plasma Exchange - methods ; Plasmapheresis ; safety ; therapeutic plasma exchange ; Transfusion Reaction ; Transplantation - methods ; Treatment Outcome</subject><ispartof>Journal of clinical apheresis, 2021-08, Vol.36 (4), p.628-633</ispartof><rights>2021 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3534-fb5862687af4ac158991063d18aa0d3e272ded5e5681314557428d8aa38630223</citedby><cites>FETCH-LOGICAL-c3534-fb5862687af4ac158991063d18aa0d3e272ded5e5681314557428d8aa38630223</cites><orcidid>0000-0002-7739-1009 ; 0000-0002-9781-0928</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjca.21904$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjca.21904$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33950554$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, John Jeongseok</creatorcontrib><creatorcontrib>Ryu, Kyong‐Suk</creatorcontrib><creatorcontrib>Kim, Jin Seok</creatorcontrib><creatorcontrib>Chung, Yousun</creatorcontrib><creatorcontrib>Kim, Hyungsuk</creatorcontrib><creatorcontrib>Hwang, Sang‐Hyun</creatorcontrib><creatorcontrib>Oh, Heung‐Bum</creatorcontrib><creatorcontrib>Ko, Dae‐Hyun</creatorcontrib><title>Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma</title><title>Journal of clinical apheresis</title><addtitle>J Clin Apher</addtitle><description>Background Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols. Aims This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation. Materials &amp; Methods Alternative use of group A or B plasma (incompatible plasma) was inevitable during the shortage of group AB plasma. Experience from select number of patients during the period of extreme group AB plasma shortage is described. Results The result of alternative use of group A or B plasma was within expectation, showing effective reduction of isoagglutinin titers for pre‐operative desensitization and efficacy for treatment of post‐operative patients. No immediate hemolytic transfusion reaction was reported. Discussion While validation in a larger cohort of patients is necessary, our limited experience have shown satisfactory clinical outcomes without adverse events. Conclusions Use of incompatible group A or B plasma is a viable option when group AB plasma is limited.</description><subject>ABO Blood-Group System</subject><subject>Agglutinins - chemistry</subject><subject>Apheresis</subject><subject>Blood Banks - supply &amp; distribution</subject><subject>Blood Group Incompatibility - therapy</subject><subject>desensitization</subject><subject>Graft Survival</subject><subject>Hemolysis</subject><subject>Humans</subject><subject>incompatible</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Patient Safety</subject><subject>Plasma</subject><subject>Plasma - immunology</subject><subject>Plasma Exchange - methods</subject><subject>Plasmapheresis</subject><subject>safety</subject><subject>therapeutic plasma exchange</subject><subject>Transfusion Reaction</subject><subject>Transplantation - methods</subject><subject>Treatment Outcome</subject><issn>0733-2459</issn><issn>1098-1101</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kT1PwzAQhi0EoqUw8AdQJBYY0vrrkngsVflSJRaYIzdx2lRJHOwY6L_HJS0DEpPtu8ePTvcidEnwmGBMJ5tMjikRmB-hIcEiCQnB5BgNccxYSDmIATqzdoMxFoLBKRowJgAD8CFq5h-ycrIrdRPoIrCyUN12d3O2bFZB2WS6bn17WamgraStZVBoE3RrZWSrXFdmh7L6ytayWakgd2b31a616aR_e9n0bk-do5NCVlZd7M8Rerufv84ew8XLw9NsuggzBoyHxRKSiEZJLAsuMwKJEARHLCeJlDhnisY0VzkoiBLCCAeIOU1y32RJxDClbIRuem9r9LtTtkvr0maqqmSjtLMpBUq5X10MHr3-g260M42fzlMgeEwAIk_d9lRmtLVGFWlrylqabUpwugsh9SGkPyF49mpvdMta5b_kYesemPTAZ1mp7f-m9Hk27ZXf2SuPZg</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Yang, John Jeongseok</creator><creator>Ryu, Kyong‐Suk</creator><creator>Kim, Jin Seok</creator><creator>Chung, Yousun</creator><creator>Kim, Hyungsuk</creator><creator>Hwang, Sang‐Hyun</creator><creator>Oh, Heung‐Bum</creator><creator>Ko, Dae‐Hyun</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7739-1009</orcidid><orcidid>https://orcid.org/0000-0002-9781-0928</orcidid></search><sort><creationdate>202108</creationdate><title>Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma</title><author>Yang, John Jeongseok ; Ryu, Kyong‐Suk ; Kim, Jin Seok ; Chung, Yousun ; Kim, Hyungsuk ; Hwang, Sang‐Hyun ; Oh, Heung‐Bum ; Ko, Dae‐Hyun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3534-fb5862687af4ac158991063d18aa0d3e272ded5e5681314557428d8aa38630223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>ABO Blood-Group System</topic><topic>Agglutinins - chemistry</topic><topic>Apheresis</topic><topic>Blood Banks - supply &amp; distribution</topic><topic>Blood Group Incompatibility - therapy</topic><topic>desensitization</topic><topic>Graft Survival</topic><topic>Hemolysis</topic><topic>Humans</topic><topic>incompatible</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Patient Safety</topic><topic>Plasma</topic><topic>Plasma - immunology</topic><topic>Plasma Exchange - methods</topic><topic>Plasmapheresis</topic><topic>safety</topic><topic>therapeutic plasma exchange</topic><topic>Transfusion Reaction</topic><topic>Transplantation - methods</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, John Jeongseok</creatorcontrib><creatorcontrib>Ryu, Kyong‐Suk</creatorcontrib><creatorcontrib>Kim, Jin Seok</creatorcontrib><creatorcontrib>Chung, Yousun</creatorcontrib><creatorcontrib>Kim, Hyungsuk</creatorcontrib><creatorcontrib>Hwang, Sang‐Hyun</creatorcontrib><creatorcontrib>Oh, Heung‐Bum</creatorcontrib><creatorcontrib>Ko, Dae‐Hyun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical apheresis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, John Jeongseok</au><au>Ryu, Kyong‐Suk</au><au>Kim, Jin Seok</au><au>Chung, Yousun</au><au>Kim, Hyungsuk</au><au>Hwang, Sang‐Hyun</au><au>Oh, Heung‐Bum</au><au>Ko, Dae‐Hyun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma</atitle><jtitle>Journal of clinical apheresis</jtitle><addtitle>J Clin Apher</addtitle><date>2021-08</date><risdate>2021</risdate><volume>36</volume><issue>4</issue><spage>628</spage><epage>633</epage><pages>628-633</pages><issn>0733-2459</issn><eissn>1098-1101</eissn><abstract>Background Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols. Aims This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation. Materials &amp; Methods Alternative use of group A or B plasma (incompatible plasma) was inevitable during the shortage of group AB plasma. Experience from select number of patients during the period of extreme group AB plasma shortage is described. Results The result of alternative use of group A or B plasma was within expectation, showing effective reduction of isoagglutinin titers for pre‐operative desensitization and efficacy for treatment of post‐operative patients. No immediate hemolytic transfusion reaction was reported. Discussion While validation in a larger cohort of patients is necessary, our limited experience have shown satisfactory clinical outcomes without adverse events. Conclusions Use of incompatible group A or B plasma is a viable option when group AB plasma is limited.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>33950554</pmid><doi>10.1002/jca.21904</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7739-1009</orcidid><orcidid>https://orcid.org/0000-0002-9781-0928</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0733-2459
ispartof Journal of clinical apheresis, 2021-08, Vol.36 (4), p.628-633
issn 0733-2459
1098-1101
language eng
recordid cdi_proquest_miscellaneous_2522400275
source Wiley Online Library - AutoHoldings Journals; MEDLINE
subjects ABO Blood-Group System
Agglutinins - chemistry
Apheresis
Blood Banks - supply & distribution
Blood Group Incompatibility - therapy
desensitization
Graft Survival
Hemolysis
Humans
incompatible
Kidney Transplantation - adverse effects
Patient Safety
Plasma
Plasma - immunology
Plasma Exchange - methods
Plasmapheresis
safety
therapeutic plasma exchange
Transfusion Reaction
Transplantation - methods
Treatment Outcome
title Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T14%3A03%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20safety%20of%20using%20incompatible%20plasma%20for%20therapeutic%20plasma%20exchange%20during%20shortage%20of%20AB%20plasma&rft.jtitle=Journal%20of%20clinical%20apheresis&rft.au=Yang,%20John%20Jeongseok&rft.date=2021-08&rft.volume=36&rft.issue=4&rft.spage=628&rft.epage=633&rft.pages=628-633&rft.issn=0733-2459&rft.eissn=1098-1101&rft_id=info:doi/10.1002/jca.21904&rft_dat=%3Cproquest_cross%3E2522400275%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2559471556&rft_id=info:pmid/33950554&rfr_iscdi=true